ClinicalTrials.gg

Depression, Postpartum clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 569 studies for Depression, Postpartum across more than 10 countries. 134 are recruiting or about to start. 437 of them are mainly about Depression, Postpartum (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 656 studies for Depression, Postpartum. How that becomes 566 here

This page counts the studies the registry files under Depression, Postpartum, and those it files under no condition that list Depression, Postpartumthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 656Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2List Depression, Postpartum as a condition, but the registry did not file them under itMost often written as “Maternal Post-partum Depression” (1) and “Sleep Quality, Depression, Postnatal Care, Single-Blind Method, Fatigue, Social Support” (1). The registry filed them under other conditions only, most often Hypertension, Pregnancy-Induced (1) and Premature Birth (1).
  3. −88Match it another way25 name it in the title, 5 in a keyword, and 58 by a synonym or other text the search reads.
  4. 566The count on this page4 of them list Depression, Postpartum in their own words; the registry filed them under no condition.

Status

Completed
330
Recruiting
87
Status unknown
46
Not yet recruiting
41
Active, not recruiting
24
Terminated
20

Phase

Phase 2
33
Phase 3
21
Phase 4
14
Phase 1
10
Early Phase 1
5

Where

United States
220
Turkey
55
Canada
50
France
24
China
20
United Kingdom
16

Who develops what

Add Depression, Postpartum to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 2 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Methylprednisolone AcetateRecent, limited
Evidence
  • NCT06057012 · Brii Biosciences Limited · Phase 2 · background · “Depo Medrol” · registered Sep 2023
—11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Aug 2027 est.brexanolone · Lipocine Inc. · Phase 3 main aimNCT07822321 Brexanolone Lifting Outcomes Of Moms — primary endpoint: Change from baseline in HAM-D17 total score compared to placebo · 120 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Depression, Postpartum studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antipsychotics 1 open · SSRIs 7

Coming up

53studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger. 13 (15%) take children under 18. 75 (86%) are for women only and 1 (1%) for men only; 40 (46%) take healthy volunteers.

Recruiting studies that take each age, of 87
AgeWomenMen
104 (5%)1 (1%)
1880 (92%)10 (11%)
3084 (97%)11 (13%)
4084 (97%)11 (13%)
5069 (79%)11 (13%)
6557 (66%)10 (11%)
7556 (64%)10 (11%)
8556 (64%)10 (11%)

Across all 569 studies, recruiting or not: 49% stop at 75 or younger and 49% at 65; 19% take children; 85% are for women only and <1% for men only; 44% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Depression, Postpartum studies take

Of 14 phase 2 interventional studies under Depression, Postpartum, half reached primary completion within 17 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 217 mo10–30 · 14 studies——
Interventional, no phase23 mo11–35 · 263 studies—23 mo11–35 · 257 studies
Observational25 mo6–52 · 53 studies—25 mo5–52 · 51 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 569. Browse all 569 → or search them.